Drugs / Hib-MenCY-TT vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00129116 | Mar → Dec 2003 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00127855 | Mar 2003 → Feb 2004 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hib-MenCY-TT vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00129116 ↗ |
| Known as | MenHibrix | “Hib-MenCY-TT vaccine (MenHibrix)” NCT00127855 ↗ |
| Modality | Vaccine | “Hib-MenCY-TT vaccine” NCT00127855 ↗ |
| Route | Intramuscular | “Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively” NCT00127855 ↗ |